Stock comparison
Harrow Health
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HROW
Harrow Health
Market cap
$1.23B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HROW | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 54C | 75B | IDXX |
| Benjamin Graham | 73D | 80A | IDXX |
| Philip Fisher | 65C | 75B | IDXX |
| Peter Lynch | 75C | 71B | HROW |
| Joel Greenblatt | 47D | 83C | IDXX |
| Charlie Munger | 55D | 87A | IDXX |
| Terry Smith | 49D | 84A | IDXX |
Side-by-side metrics
| Metric | HROW | IDXX |
|---|---|---|
| Market cap | $1.23B | $44.12B |
| P/E (TTM) | - | 39.0x |
| EV/EBIT | 35.2x | 31.6x |
| ROIC (TTM) | 8.55% | 40.66% |
| Gross margin | 74.11% | 62.05% |
| Net margin | -5.57% | 24.63% |
| Revenue CAGR 5y | 39.22% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 10.5x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HROW leads on
- P/E (TTM)-vs 39.0x+151%
- Revenue CAGR 5y39.22%vs 7.56%+81%
- Gross margin74.11%vs 62.05%+16%
IDXX leads on
- Net margin24.63%vs -5.57%+123%
- Market cap$44.12Bvs $1.23B+97%
- Debt / Equity0.7xvs 10.5x+93%
- ROIC (TTM)40.66%vs 8.55%+79%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.